BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cytopia Pty. Ltd. And Myomatrix Therapeutics LLC To Collaborate On Cardiovascular Disorders


10/19/2005 5:09:31 PM

RENSSELAER, N.Y., and MELBOURNE, Australia, Dec. 15 /PRNewswire/ -- Australian biotech Cytopia and New York based Myomatrix Therapeutics today announced a collaboration that could lead to breakthrough treatments for heart failure and hypertension.

Myomatrix has worldwide exclusive rights to develop and commercialize therapies for certain cardiovascular diseases by inhibiting a kinase target. This target is a breakthrough approach already validated in animal studies, and represents a completely novel mechanism for the treatment of heart failure and hypertension.

Cytopia has worldwide exclusive rights to several kinase targets and has already developed highly potent and specific inhibitors.

Cytopia head Dr Kevin Healey said, "Under the jointly-funded work program, Cytopia will provide its specific inhibitors to Myomatrix for testing in animal models and the data generated will be jointly owned. The first product is being targeted at a chronic "orphan" disease, which has no current treatment and a potential market of US$500 million. The next products will target heart failure and hypertension."

Dr Shreefal Mehta, the CEO of Myomatrix said, "The collaboration with Cytopia accelerates Myomatrix's program forward by at least two years. We are very impressed with the capabilities of Cytopia and its strong intellectual property position in the kinase area."

Dr Healey said the collaboration with Myomatrix opened up a major new therapeutic area for Cytopia's technology in addition to immune diseases and cancer, in which it had already made major breakthroughs. "Myomatrix has extremely strong skills in the biological and clinical aspects of these diseases, whereas Cytopia provides the necessary drug discovery and medicinal chemistry expertise," he said. "Upon success in this research collaboration, we do not discount the possibility of the two companies operating more closely in the near future."

ABOUT THE COMPANIES

Myomatrix Therapeutics LLC is a privately held biopharmaceutical company based in Rensselaer, New York, with core expertise in developing therapies for cardiovascular diseases. http://www.myomatrix.com/.

Cytopia is a Melbourne-based drug discovery company focused on the treatment of immune diseases and cancer. It is an 80%-owned subsidiary of Medica Holdings Limited . http://www.cytopia.com.au/

Medica Holdings Ltd, an ASX-listed Pooled Development Fund, specialises in investing in the biotechnology sector. Visit our website at: http://www.medica.com.au/.

Myomatrix Therapeutics LLC

CONTACT: Dr Shreefal Mehta, Chief Executive Officer of MyomatrixTherapeutics LLC, +1-518-331-8078, smehta@myomatrix.com; or Dr Kevin Healey,Chief Executive Officer of Medica Holdings Limited, +0409-413-402,info@medica.com.au



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES